Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor, was given on top of empagliflozin, an SGLT2 inhibitor, suggesting additive efficacy1 Potential new treatment builds on Boehringer…